Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-P15-041 vs 68Ga-PSMA-11 in Prostate Bone Metastasis
NCT05627778Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Countries
- 1
- Sponsor
- Peking Union Medical College Hospital
- Modality
- PET/CT (Positron Emission Tomography/Computed Tomography)
- Drugs
- [68Ga]Ga-P15-041
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label, single-arm trial of [68Ga]Ga-P15-041 in prostate cancer (PCa), sponsored by Peking Union Medical College Hospital. Primary endpoints: detection capability of bone metastasis at 1 year and SUVmax of bone metastasis at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
68Ga-PSMA-11 and 68Ga-P15-041 PET/ CT scan
Patients receive both 68Ga-PSMA-11 and 68Ga-P15-041 scans within one week.
03
Who it enrols
Patients with confirmed or suspected prostate bone metastasis.
04
Endpoints
Primary
detection capability of bone metastasis
SUVmax of bone metastasis
Secondary
PSMA expression and SUV
Beyond the preview
Go deeper on NCT05627778.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627778.